Octapharma
Clinical trials sponsored by Octapharma, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could help Immune-Compromised patients fight infections Results expected Sep 2026 (estimated)
- New drug aims to stop swelling attacks in hereditary angioedema Results expected Dec 2026 (estimated)
- New hope for rare clotting disorder: drug aims to prevent dangerous clots during surgery and delivery Results expected Dec 2026 (estimated)
- New study tests clotting drug for safer surgery in women with hemophilia a Results expected Feb 2027 (estimated)
-
Can antibody infusions shield CLL patients from deadly infections?
Disease control CompletedThis study tested whether regular infusions of Panzyga (a concentrated antibody solution from donated blood) could prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. The trial included 247 adults with CLL who were recei…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for toddlers with rare bleeding disorder: wilate shows promise
Disease control CompletedThis study tested a medicine called wilate in 12 children under 6 years old with severe von Willebrand disease, a bleeding disorder. The goal was to see if regular infusions of wilate could prevent bleeding episodes over 12 months. Researchers measured how many bleeds occurred, h…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could an immune treatment ease severe OCD in kids with PANS?
Symptom relief CompletedThis study tested whether a medicine called Panzyga (given through a vein) can reduce obsessive-compulsive symptoms in children aged 6 to 17 with a condition called PANS or PANDAS. These children experience a sudden, severe onset of OCD and other neuropsychiatric problems. The st…
Phase 3 • Sponsor: Octapharma • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC